Pathophysiology of psoriasis

Indian Journal of Dermatology, Venereology and Leprology

Volumn 79, Issue SUPPL. 1, 2013, Pages

  Mahajan, Rahul ^a   Handa, Sanjeev ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

pathogenesis; Psoriasis; skin barrier dysfunction; Th17 cells

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; APILIMOD; BRIAKINUMAB; BRODALUMAB; CORNEODESMOSIN; CYCLOSPORIN; DESMOSINE; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA C ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 23P19; INTERLEUKIN 4; IXEKIZUMAB; METHOTREXATE; PSORS1 PROTEIN; SECUKINUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB;

ADAPTIVE IMMUNITY; ARTICLE; ATOPIC DERMATITIS; CELL DIFFERENTIATION; CHROMOSOME 6P; CHROMOSOME 8P; CROHN DISEASE; DIABETES MELLITUS; ENDOGENOUS RETROVIRUS; ENDOPLASMIC RETICULUM; ENVIRONMENTAL FACTOR; EPITHELIUM CELL; GENETIC ASSOCIATION; GENETIC RISK; GENOME IMPRINTING; HAPLOTYPE; HEREDITY; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; INHERITANCE; INJURY; INNATE IMMUNITY; KERATINOCYTE; LINKAGE ANALYSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MEIOSIS; MENTAL STRESS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ERYTHRODERMA; RELAPSE; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL; TH17 CELL; TONSILLECTOMY; ULTRAVIOLET RADIATION;

ADAPTIVE IMMUNITY; HUMANS; IMMUNITY, INNATE; PSORIASIS; SKIN; TH1 CELLS; TH17 CELLS;

EID: 84883176763     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.115505     Document Type: Article

References (67)

1. Christophers E. Psoriasis - Epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20.
2. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: Current and emerging directed therapies. Ann Rheum Dis 2005;64:ii87-90.
3. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71.
4. Langley RG. Effective and sustainable biologic treatment of psoriasis: What can we learn from new clinical data? J Eur Acad Dermatol Venereol 2012;26:S21-9.
5. Mattozzi C, Richetta AG, Cantisani C, Macaluso L, Calvieri S. Psoriasis: New insight about pathogenesis, role of barrier organ integrity, NLR /CATERPILLER family genes and microbial flora. J Dermatol 2012;39:752-60.
6. Nanda A, Kaur S, Kaur I, Kumar B. Childhood psoriasis: An epidemiologic survey of 112 patients. Pediatr Dermatol 1990;7:19-21.
7. al-Fouzan AS, Nanda A. A survey of childhood psoriasis in Kuwait. Pediatr Dermatol 1994;11:116-9.
8. Richardson SK, Gelfand JM. Update on the natural history and systemic treatment of psoriasis. Adv Dermatol 2008;24:171-96.
9. Brandrup F, Hauge M, Henningsen J, Eriksen B. Psoriasis in an unselected series of twins. Arch Dermatol 1978;114:874-8.
10. Burden AD, Javed S, Bailey M, Hodgins M, Connor M, Tillman D. Genetics of psoriasis: Paternal inheritance and a locus on chromosome 6p. J Invest Dermatol 1998;110:958-60.
11. Trembath RC, Clough TL, Rosbotham JL. Identification of a major susceptibility gene locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Human Mol Genet 1997;6:813-20.
12. Chen H, Poon A, Yeung C, Helms C, Pons J, Bowcock AM. A genetic risk score combining ten psoriasis risk loci improves disease prediction. PLoS One 2011;6:e19454.
13. Umapathy S, Pawar A, Mitra R, Khuperkar D, Devaraj JP, Ghosh K, et al. Hla-a and hla-B alleles associated in psoriasis patients from mumbai, Western India. Indian J Dermatol 2011;56:497-500.
14. Guilhou JJ, Molès JP. New hypotheses in the genetics of psoriasis and other 'complex' diseases. Dermatology 2008;216:87-92.
15. Theeuwes M, Morhenn V. Allelic instability in the mitosis model and the inheritance of psoriasis. J Am Acad Dermatol 1995;32:44-52.
16. Nair RP, Stuart PE, Nistor I, Hiremagalore R, Chia NV, Jenisch S, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006;78:827-51.
17. Bergboer JG, Zeeuwen PL, Schalkwijk J. Genetics of Psoriasis: Evidence for Epistatic Interaction between Skin Barrier Abnormalities and Immune Deviation. J Invest Dermatol 2012;132:2320-1.
18. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008;128:1653-61.
19. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009;41:199-204.
20. Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk- Olthuis D, et al. Psoriasis is associated with increased betadefensin genomic copy number. Nat Genet 2008;40:23-5.
21. de Cid R, Riveira-Munoz E, Zeeuwen PL, Robarge J, Liao W, Dannhauser EN, et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet 2009;41:211-5.
22. Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011;365:620-8.
23. Lich JD, Ting JP. CATERPILLER (NLR) family members as positive and negative regulators of inflammatory responses. Proc Am Thorac Soc 2007;4:263-6.
24. Petnicki-Ocwieja T, Hrncir T, Liu YJ, Biswas A, Hudcovic T, Tlaskalova-Hogenova H, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci U S A 2009;106:15813-8.
25. Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 2010;49:1351-61.
26. Wolters M. Diet and psoriasis: Experimental data and clinical evidence. Br J Dermatol 2005;153:706-14.
27. Farkas A, Kemény L, Széll M, Dobozy A, Bata-Csörgo Z. Ethanol and acetone stimulate the proliferation of HaCaT keratinocytes: The possible role of alcohol in exacerbating psoriasis. Arch Dermatol Res 2003;295:56-62.
28. Cheng SE, Luo SF, Jou MJ, Lin CC, Kou YR, Lee IT, et al. Cigarette smoke extract induces cytosolic phospholipase A2 expression via NADPH oxidase, MAPKs, AP-1, and NF-kappaB in human tracheal smooth muscle cells. Free Radic Biol Med 2009;46:948-60.
29. Thappa DM. The isomorphic phenomenon of Koebner. Indian J Dermatol Venereol Leprol 2004;70:187-9.
30. Evers AW, Verhoeven EW, Kraaimaat FW, de Jong EM, de Brouwer SJ, Schalkwijk J, et al. How stress gets under the skin: Cortisol and stress reactivity in psoriasis. Br J Dermatol 2010;163:986-91.
31. Sagi L, Trau H. The Koebner phenomenon. Clin Dermatol 2011;29:231-6.
32. Blok S, Vissers WH, van Duijnhoven M, van de Kerkhof PC. Aggravation of psoriasis by infections: A constitutional trait or a variable expression? Eur J Dermatol 2004;14:259-61.
33. Johnston A, Gudjonsson JE, Sigmundsdottir H, Love TJ, Valdimarsson H. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol 2004;138:83-93.
34. Baker BS, Ovigne JM, Fischetti VA, Powles A, Fry L. Selective response of dermal Th-1 cells to 20-50 kDa streptococcal cell-wall proteins in chronic plaque psoriasis. Scand J Immunol 2003;58:335-41.
35. Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, Olafsson JH, Sigurdsson MI, Petersen H, et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol 2012;188:5160-5.
36. Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A. Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007;9:461-7.
37. Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 2010;29:3-9.
38. Krueger G, Ellis CN. Psoriasis - Recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005; 53:S94-100.
39. Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986;256:3110-6.
40. Tomic-Canic M, Komine M, Freedberg IM, Blumenberg M. Epidermal signal transduction and transcription factor activation in activated keratinocytes. J Dermatol Sci 1998;17:167-81.
41. Van Ruissen F, Van de Kerkhof PC, Schalkwijk J. Signal transduction pathways in epidermal proliferation and cutaneous inflammation. Clin Dermatol 1995;13:161-90.
42. Barker JN. The pathophysiology of psoriasis. Lancet 1991; 338:227-30.
43. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007;19:281-6.
44. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8.
45. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the Th17 lineage. Nature 2006;441:231-4.
46. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30.
47. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008;28:454-67.
48. Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al. The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings. J Invest Dermatol 2013;133:17-26.
49. Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: An antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol 2012;24:126-35.
50. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6.
51. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203:2271-9.
52. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suárez-Fariñas M, Cardinale I, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008;159:1092-102.
53. Wada Y, Cardinale I, Khatcherian A, Chu J, Kantor AB, Gottlieb AB, et al. Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PLoS One 2012;7:e35069.
54. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-á therapy. Arthritis Res Ther 2011;13:R126.
55. Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG. Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci U S A 2009;106:21795-800.
56. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-6.
57. Creamer D, Allen MH, Sousa A, Poston R, Barker JN. Localization of endothelial proliferation and microvascular expansion in active plaque psoriasis. Br J Dermatol 1997;136:859-65.
58. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing ãä T cells in skin inflammation. Immunity 2011;35:596-610.
59. Mabuchi T, Takekoshi T, Hwang ST. Epidermal CCR6+ ãä T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J Immunol 2011;187:5026-31.
60. Laggner U, Di Meglio P, Perera GK, Hundhausen C, Lacy KE, Ali N, et al. Identification of a novel proinflammatory human skin-homing Vã9Vä2 T cell subset with a potential role in psoriasis. J Immunol 2011;187:2783-93.
61. Hollox EJ, Armour JA, Barber JC. Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet 2003;73:591-600.
62. Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D, et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008;40:23-5.
63. Jansen PA, Rodijk-Olthuis D, Hollox EJ, Kamsteeg M, Tjabringa GS, de Jongh GJ, et al. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One 2009;4:e4725.
64. Lee Y, Je YJ, Lee SS, Li ZJ, Choi DK, Kwon YB, et al. Changes in transepidermal water loss and skin hydration according to expression of aquaporin-3 in psoriasis. Ann Dermatol 2012;24:168-74.
65. Bergboer JG, Tjabringa GS, Kamsteeg M, van Vlijmen-Willems IM, Rodijk-Olthuis D, Jansen PA, et al. Psoriasis risk genes of the late cornified envelope-3 group are distinctly expressed compared with genes of other LCE groups. Am J Pathol 2011;178:1470-7.
66. de Guzman Strong C, Conlan S, Deming CB, Cheng J, Sears KE, Segre JA. A milieu of regulatory elements in the epidermal differentiation complex syntenic block: Implications for atopic dermatitis and psoriasis. Hum Mol Genet 2010;19:1453-60.
67. Lebwohl M. Psoriasis. Lancet 2003;361:1197-204.